Concomitant active inflammation of myocardium and thyroid, incidental finding in COVID-19 pandemic: A case report

Golnaz Houshmand1 | Seyyed Mojtaba Ghorashi2 | Fatemeh Mirrazeghi3 | Negar Omidi2

1Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
2Cardiology Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
3Gilan University of Medical Sciences, Rasht, Iran

Correspondence
Negar Omidi, Cardiology Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Email: negar.omidi@gmail.com

Abstract
SARS-CoV-2 could affect every organ either directly or indirectly. We describe a young, healthy man diagnosed with COVID-19 whose inaugural presentation was concurrent myocarditis and incidental thyroiditis in cardiac magnetic resonance imaging within two months post-recovery. This case illustrates the ongoing pro-inflammatory process several months’ post-COVID-19 recovery.

KEYWORDS
cardiac magnetic resonance, case report, COVID-19, myocarditis, SARS-CoV-2, Thyroid

1 | INTRODUCTION

Coronavirus 2019 Disease (COVID-19) could impact all organs directly or indirectly. COVID-19-induced myocardial injury has an incidence of somewhere between 7% to 23% and is also associated with increased mortality.1,2 We herein describe a young man with a history of COVID-19 infection, who was referred for evaluation of chest pain and left ventricular (LV) systolic dysfunction with an incidental finding of thyroiditis around two months of post-recovery. To the best of our knowledge, there are no papers published so far on concomitant myocarditis and thyroiditis, several months after the recovery of COVID-19. This case highlights the fact that a systematic pro-inflammatory process would continue months after the COVID-19 infection. Figure 1 illustrates the timeline diagram outlining patient’s clinical course. The report conformed to the principles of Helsinki.

1.1 | CASE PRESENTATION

A 25-year-old man with a 1-week history of dyspnea, palpitation, fever (body temperature of 38°C), and a sore throat was diagnosed with COVID-19 infection in August 2020. The diagnosis was made based on the clinical symptoms; as other roommates were also diagnosed with COVID-19 based on real-time polymerase chain reaction (RT-PCR). His past medical and family history were unremarkable. He self-isolated himself and did not admitted to the hospital or received any antiviral medications and recovered from COVID-19 in two weeks. Since then, the patient had a complaint of persistent atypical chest pain and dyspnea on exertion and was referred to the cardiologist in November 2020, he also mentioned ongoing sore throat. The electrocardiogram demonstrated a nonspecific change in repolarization, and the transthoracic echocardiography revealed normal left ventricular size with a left ventricular
ejection fraction (LVEF) of 45%. Laboratory examinations demonstrated a C-reactive protein (CRP) level of 9.9 mg/dl (normal range <0.5 mg/dl), white blood cell count of 7100/µl, with a lymphocyte percentage of 18.8% and high troponin I level. The cardiac magnetic resonance imaging (CMR) depicted mildly increased LV-indexed volumes with moderately reduced ejection fraction (LVEF of 44%, LV end-diastolic volume index of 101 ml/m², global longitudinal strain of −12.5%, and global circumferential strain of −16.01%). The right ventricular indexed volumes and ejection fraction were normal (RVEF: 51% and RV end-diastolic volume index: 95 ml/m²). The short tau inversion recovery sequences (STIR) revealed an increased signal intensity in the basal to mid part of the septum and lateral walls. The late gadolinium enhancement (LGE) images showed a subepicardial and mid-wall enhancement in the basal to midpart of the septum and lateral walls (Figure 2). There was mild bilateral pleural effusion with evidence of pleural-based infiltration in the left lower lung. The CMR finding is in keeping with active myocarditis. The incidental extra-cardiac finding in anatomic images was irregular and large right thyroid lobe with fluid containing lesions and heterogeneous signal intensity (Figure 3) which was confirmed by thyroid sonography. The thyroid function test revealed a thyroxin (T4) level of 9.90 mcg/dl (normal range: 4.2–12.5 mcg/dl), triiodothyronine (T3) of 2.23 nmol/L (normal range: 1.10–2.90 nmol/L), and thyroid-stimulating hormone (TSH) of 1.3 mIU/ml (normal range: 0.3–5.5 mIU/ml). According to the clinical finding of neck swelling and thyroid tenderness in the physical

**TIMELINE**

| Time   | Events                                                                 |
|--------|------------------------------------------------------------------------|
| Day 1-7| 1-week history of dyspnea, palpitation, fever (body temperature of 38 °C), and a sore throat (COVID-19 in other roommates ten days ago) |
| Day 7-28 | self-isolated at home with only mild constitutional symptoms, no antiviral treatment |
| Day 28-66 | persistent atypical chest pain and dyspnea on exertion, neck swelling |
| Day 66 | refer to a cardiologist, ECG had repolarization abnormalities, TTE revealed normal LV size with LVEF: 45%; CRP: 9.9 mg/dl; thyroid tenderness |
| Day 70 | CMR revealed active myocarditis with evidence of thyroiditis |

**Figure 1** Timeline diagram outlining patient’s clinical course

**Figure 2** STIR and late gadolinium enhancement sequences (LGE). (A) STIR short axis sequence revealed increased signal intensity and edema in the basal to midpart of septum and lateral walls. (B) LGE sequence revealed subepicardial and mid-wall enhancement in the basal to midpart of the septum and lateral walls.
examination, the diagnosis of concomitant subacute thyroiditis and active myocarditis was considered, and treatment with a beta-blocker, angiotensin-converting enzyme inhibitor, and anti-inflammatory agent were started, and follow-up was planned.

2 | DISCUSSION

In the present case, we addressed the COVID-19-related delayed systemic inflammatory reaction in both the myocardium and thyroid in a young man after an episode of COVID-19 with unremarkable initial symptoms. The diagnostic workup showed concurrent active myocarditis with thyroiditis within months after recovery.

COVID-19 infection, even mild, promotes a pro-inflammatory state such as inducing oxidative stress and cytokine surge as evident by increased plasma interleukin, CRP, and monocyte chemoattractant protein-1 (MCP-1) which could mediate acute myocardial injury even after recovery. According to previous studies, a high burden of inflammation is associated with cardiovascular involvement. The mechanism of myocarditis is considered to be immune-mediated indirect myocardial inflammation due to inflammatory cytokines or direct viral inclusion. The reported frequency of CMR-documented cardiac involvement in patients with ongoing symptoms was 58%. Puntmann and Rajpal studies also showed a high frequency of persistent inflammation in patients with recovered COVID-19 which were independent of severity at presentation.

The frequency of thyroid dysfunction in patients with mild to moderate COVID-19 is estimated to be 13.2%. Reports of COVID-19-induced thyroiditis suggest either a direct or indirect effect on thyroid function, with low T3 and serum TSH levels appear to have prognostic significance.

The presentation of thyroid disorder in COVID-19 could be hypothyroidism, thyrotoxicosis, and nonthyroidal illness syndrome. Also, subacute thyroiditis could occur in the post-recovery phase. The underlying mechanism for decreased TSH level in the acute phase of severe acute respiratory distress syndrome (SARS) could be central hypothyroidism due to reversible hypophysitis or hypothalamic effect as an adaptation to a severe illness in intensive care unit (ICU) setting. According to reports, hypothyroidism could suggest a possible mechanism of symptoms in the post-COVID-19 recovery phase. We assumed that COVID-19 patients could be prone to either virus or immune-mediated thyroid damage with the same mechanisms of myocardial involvement resulting in the development of thyroiditis.

Since post-COVID-19 thyroid disorder would affect general patients’ condition and myocardium, struggling with complicated cases is crucial to keep the probable sequels in mind.

3 | CONCLUSION

Patients recovered from COVID-19 may suffer from a wide range of symptoms and also may have a constant inflammatory state and late sequels in different organs. This case suggests that one should be aware of the presence of we presented delayed thyroiditis and myocarditis in a recovery phase. The World Health Organization had not recommended the assessment of thyroid function for COVID-19. The diagnosis of thyroiditis in the post-COVID-19 stage could be difficult considering the nonspecific symptoms. However, timely recognition is critical. There remains poor insight into the extent of the pro-inflammatory process in COVID-19 patients; a cohort study of patients with myocardial and thyroid inflammation could be of value.
ACKNOWLEDGMENTS
The authors acknowledge all staffs of Rajaei Cardiovascular Research Center and we thank the patient's family for their collaboration.

CONFLICT OF INTEREST
Nothing has been declared.

AUTHOR CONTRIBUTIONS
NO and GH contributed to the conception of the work MGH and FM contributed to data acquisition. All authors have approved the submitted version.

ETHICAL APPROVAL
The project was approved by the Medical Ethics Committee of Rajaei Cardiovascular Research Center. The authors confirm that the report conformed to the principles of Helsinki.

CONSENT
The informed consent for publication was obtained from the patient.

DATA AVAILABILITY STATEMENT
The data of this article will be shared on request.

ORCID
Golnaz Houshmand © https://orcid.org/0000-0001-5026-5101
Seyyed Mojtaba Ghorashi © https://orcid.org/0000-0002-7933-5633
Negar Omidi © https://orcid.org/0000-0003-2344-1661

REFERENCES
1. Pirzada A, Mokhtar AT, Moeller AD. COVID-19 and myocarditis: What do we know so far? CJC Open. 2020;2(4):278-285.
2. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiology. 2020;5(7):802
3. Pal R, Banerjee M. COVID-19 and the endocrine system: exploring the unexplored. J Endocrinol Invest. 2020;43(7):1027-1031
4. Inciardi RM, Solomon SD, Ridker PM, Metra M. Coronavirus 2019 disease (COVID-19), systemic inflammation, and cardiovascular disease. J Am Heart Assoc. 2020;9(16):e017756.
5. Dworakowska D, Grossman AB. Thyroid disease in the time of COVID-19. Endocrine. 2020;7:1-4.
6. Huang L, Zhao P, Tang D, et al. Cardiac involvement in recovered COVID-19 patients identified by magnetic resonance imaging. JACC Cardiovasc Imaging. 2020;13(11):2330-2339.
7. Rajpal S, Tong MS, Borchers J, et al. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol. 2020;313(3):264-274. https://doi.org/10.1001/jamacardio.2020.4916
8. Puntmann VO, Carej ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265-1273.
9. Lui DT, Lee CH, Chow WS, et al. Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 patients with COVID-19. J Clin Endocrinol Metab. 2021;106(2):e926-e935.
10. Tomer Y, Huber A. The etiology of autoimmune thyroid disease: a story of genes and environment. J Autoimmun. 2009;32(3-4):231-239.
11. Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimbo P. Impact of COVID-19 on the thyroid gland: an update. Rev Endocr Metab Disord. 2020;25:1-3.
12. Brancatella A, Ricci D, Cappellani D, et al. Is subacute thyroiditis an underestimated manifestation of SARS-CoV-2 infection? Insights from a case series. J Clin Endocrinol Metab. 2020;105(10):e3742-e3746.
13. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. https://doi.org/10.1136/bmj.m1091
14. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region—case series. N Engl J Med. 2020;382(21):2012-2022.
15. Chrousos GP, Kaltsas G. Post-SARS sickness syndrome manifestations and endocrinopathy: how, why, and so what? Clin Endocrinol. 2005;63(4):363.
16. Wang W, Ye YX, Yao H, Sun LQ, Wang AS, Wang ZY. Evaluation and observation of serum thyroid hormone and parathyroid hormone in patients with severe acute respiratory syndrome. J Chin Antituberculous Assoc. 2003;25:232-234.
17. Wei L, Sun S, Xu C-H, et al. Pathology of the thyroid in severe acute respiratory syndrome. Hum Pathol. 2007;38(1):95-102.
18. Leow MK, Kwek DS, Ng AW, Ong KC, Kaw GJ, Lee LS. Hypocortisolism in survivors of severe acute respiratory syndrome (SARS). Clin Endocrinol. 2005;63(2):197-202.

How to cite this article: Houshmand G, Ghorashi SM, Mirrazeghi F, Omidi N. Concomitant active inflammation of myocardium and thyroid, incidental finding in COVID-19 pandemic: A case report. Clin Case Rep. 2021;9:e04998. https://doi.org/10.1002/ccr3.4998